You are here

Noxafil Delayed-Release Tablets Approved

New formulation for prevention of Aspergillus and Candida infections (November 26)

A new formulation for posaconazole (Noxafil, Merck) 100 mg delayed-release tablets has been approved. Patients take a loading dose of 300 mg (three 100-mg delayed-release tablets) twice daily on the first day, followed by a once-daily maintenance dose of 300 mg (three 100-mg delayed-release tablets) starting on the second day of therapy.

Merck also sells a 40-mg/mL oral suspension, which is taken three times daily.

The delayed-release tablets and oral suspension are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age and older with a severely compromised immune system, such as hematopoietic stem-cell transplant recipients with graft-versus-host disease or those with hematological malignancies with prolonged neutropenia resulting from chemotherapy.

Posaconazole delayed-release tablets and the oral suspension are not to be used interchangeably because of differences in the dosing of each formulation.

[Source: Merck; November 26, 2013.]

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens